Drug Profile
Research programme: influenza vaccines - BIKEN/AstraZeneca
Latest Information Update: 06 Aug 2021
Price :
$50
*
At a glance
- Originator Biken
- Developer BIKEN
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Influenza-virus-infections(Prevention) in Japan
- 29 Sep 2008 Early research in Influenza virus infections in Japan (unspecified route)